APO Research
Talk to an analyst

APO RESEARCH · REPORT

Novel Oral AntiCoagulants (NOAC)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Novel Oral AntiCoagulants (NOAC) Industry Growth and Trends Forecast to 2032

26 December 2025119 pages

Choose your research edition.

Industry ResearchNovel Oral AntiCoagulants (NOAC) Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Novel Oral AntiCoagulants (NOAC) Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Novel Oral AntiCoagulants (NOAC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Novel Oral AntiCoagulants (NOAC) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Novel Oral AntiCoagulants (NOAC) Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Novel Oral AntiCoagulants (NOAC) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Novel Oral AntiCoagulants (NOAC) include Armatheon, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Daiichi Sankyo and Marathon Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Novel Oral AntiCoagulants (NOAC) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Novel Oral AntiCoagulants (NOAC) market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Novel Oral AntiCoagulants (NOAC) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Novel Oral AntiCoagulants (NOAC).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Novel Oral AntiCoagulants (NOAC) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Novel Oral AntiCoagulants (NOAC) Market by Company

Armatheon

Aspen

Boehringer Ingelheim

Bristol-Myers Squibb

Cellceutix

Cosmo Pharmaceuticals

CSL Behring

Daiichi Sankyo

Marathon Pharmaceuticals

Ockham Biotech

Perosphere

AstraZeneca

Bayer

GSK

Johnson & Johnson

Sanofi

Eisai

Novel Oral AntiCoagulants (NOAC) Segment by Type

Direct Thrombin Inhibitors

Direct Factor Xa Inhibitors

Novel Oral AntiCoagulants (NOAC) Segment by Application

Hemodialysis

Deep Vein Thrombosis (DVT)

Acute Coronary Syndrome

Pulmonary Embolism

Others

Novel Oral AntiCoagulants (NOAC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Oral AntiCoagulants (NOAC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Novel Oral AntiCoagulants (NOAC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Oral AntiCoagulants (NOAC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Novel Oral AntiCoagulants (NOAC) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Novel Oral AntiCoagulants (NOAC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Direct Thrombin Inhibitors Table 2. Major Company of Direct Factor Xa Inhibitors Table 3. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 5. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Type (2021-2026) Table 6. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (US$ Million) Table 7. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Type (2021-2026) Table 8. Global Novel Oral AntiCoagulants (NOAC) Price by Type (2021-2026) & (US$/Unit) Table 9. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 10. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Type (2027-2032) Table 11. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (US$ Million) Table 12. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Type (2027-2032) Table 13. Global Novel Oral AntiCoagulants (NOAC) Price by Type (2027-2032) & (US$/Unit) Table 14. North America Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 15. North America Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 17. Europe Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 19. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 21. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 23. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (US$ Million) Table 24. Novel Oral AntiCoagulants (NOAC) Industry Trends Table 25. Novel Oral AntiCoagulants (NOAC) Industry Drivers Table 26. Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges Table 27. Novel Oral AntiCoagulants (NOAC) Industry Restraints Table 28. Global Novel Oral AntiCoagulants (NOAC) Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Company (2021-2026) Table 30. Global Novel Oral AntiCoagulants (NOAC) Sales by Company (2021-2026) & (W Units) Table 31. Global Novel Oral AntiCoagulants (NOAC) Sales Share by Company (2021-2026) Table 32. Global Novel Oral AntiCoagulants (NOAC) Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Novel Oral AntiCoagulants (NOAC) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Novel Oral AntiCoagulants (NOAC) Major Company Production Sites and Headquarters Table 35. Global Novel Oral AntiCoagulants (NOAC) Company, Product Type & Application Table 36. Global Novel Oral AntiCoagulants (NOAC) Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Novel Oral AntiCoagulants (NOAC) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Novel Oral AntiCoagulants (NOAC) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2026) & (W Units) Table 41. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Region (2021-2026) Table 42. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2026) & (US$ Million) Table 43. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Region (2021-2026) Table 44. Global Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2027-2032) & (W Units) Table 46. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Region (2027-2032) Table 47. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2027-2032) & (US$ Million) Table 48. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Region (2027-2032) Table 49. Global Novel Oral AntiCoagulants (NOAC) Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 52. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Application (2021-2026) Table 53. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (US$ Million) Table 54. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Application (2021-2026) Table 55. Global Novel Oral AntiCoagulants (NOAC) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 57. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Application (2027-2032) Table 58. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (US$ Million) Table 59. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Application (2027-2032) Table 60. Global Novel Oral AntiCoagulants (NOAC) Price by Application (2027-2032) & (US$/Unit) Table 61. North America Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 62. North America Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 64. Europe Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 66. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 68. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 70. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (US$ Million) Table 71. Armatheon Company Information Table 72. Armatheon Business Overview Table 73. Armatheon Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 75. Armatheon Recent Development Table 76. Aspen Company Information Table 77. Aspen Business Overview Table 78. Aspen Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 80. Aspen Recent Development Table 81. Boehringer Ingelheim Company Information Table 82. Boehringer Ingelheim Business Overview Table 83. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 85. Boehringer Ingelheim Recent Development Table 86. Bristol-Myers Squibb Company Information Table 87. Bristol-Myers Squibb Business Overview Table 88. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 90. Bristol-Myers Squibb Recent Development Table 91. Cellceutix Company Information Table 92. Cellceutix Business Overview Table 93. Cellceutix Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 95. Cellceutix Recent Development Table 96. Cosmo Pharmaceuticals Company Information Table 97. Cosmo Pharmaceuticals Business Overview Table 98. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 100. Cosmo Pharmaceuticals Recent Development Table 101. CSL Behring Company Information Table 102. CSL Behring Business Overview Table 103. CSL Behring Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 105. CSL Behring Recent Development Table 106. Daiichi Sankyo Company Information Table 107. Daiichi Sankyo Business Overview Table 108. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 110. Daiichi Sankyo Recent Development Table 111. Marathon Pharmaceuticals Company Information Table 112. Marathon Pharmaceuticals Business Overview Table 113. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 115. Marathon Pharmaceuticals Recent Development Table 116. Ockham Biotech Company Information Table 117. Ockham Biotech Business Overview Table 118. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 120. Ockham Biotech Recent Development Table 121. Perosphere Company Information Table 122. Perosphere Business Overview Table 123. Perosphere Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 125. Perosphere Recent Development Table 126. AstraZeneca Company Information Table 127. AstraZeneca Business Overview Table 128. AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 130. AstraZeneca Recent Development Table 131. Bayer Company Information Table 132. Bayer Business Overview Table 133. Bayer Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 135. Bayer Recent Development Table 136. GSK Company Information Table 137. GSK Business Overview Table 138. GSK Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 140. GSK Recent Development Table 141. Johnson & Johnson Company Information Table 142. Johnson & Johnson Business Overview Table 143. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 145. Johnson & Johnson Recent Development Table 146. Sanofi Company Information Table 147. Sanofi Business Overview Table 148. Sanofi Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 150. Sanofi Recent Development Table 151. Eisai Company Information Table 152. Eisai Business Overview Table 153. Eisai Novel Oral AntiCoagulants (NOAC) Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 155. Eisai Recent Development Table 156. North America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 157. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 158. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2026) Table 159. North America Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032) & (W Units) Table 160. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share Forecast by Country (2027-2032) Table 161. North America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. North America Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026) & (US$ Million) Table 163. North America Novel Oral AntiCoagulants (NOAC) Market Share by Country (2021-2026) Table 164. North America Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. North America Novel Oral AntiCoagulants (NOAC) Market Share Forecast by Country (2027-2032) Table 166. Europe Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 167. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 168. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2026) Table 169. Europe Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032) & (W Units) Table 170. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share Forecast by Country (2027-2032) Table 171. Europe Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026) & (US$ Million) Table 173. Europe Novel Oral AntiCoagulants (NOAC) Market Share by Country (2021-2026) Table 174. Europe Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Europe Novel Oral AntiCoagulants (NOAC) Market Share Forecast by Country (2027-2032) Table 176. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 177. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 178. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2026) Table 179. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032) & (W Units) Table 180. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share Forecast by Country (2027-2032) Table 181. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026) & (US$ Million) Table 183. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Share by Country (2021-2026) Table 184. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Share Forecast by Country (2027-2032) Table 186. Latin America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 187. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 188. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2026) Table 189. Latin America Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032) & (W Units) Table 190. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share Forecast by Country (2027-2032) Table 191. Latin America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Latin America Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026) & (US$ Million) Table 193. Latin America Novel Oral AntiCoagulants (NOAC) Market Share by Country (2021-2026) Table 194. Latin America Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Latin America Novel Oral AntiCoagulants (NOAC) Market Share Forecast by Country (2027-2032) Table 196. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 197. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 198. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2026) Table 199. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032) & (W Units) Table 200. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share Forecast by Country (2027-2032) Table 201. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 202. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026) & (US$ Million) Table 203. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Share by Country (2021-2026) Table 204. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 205. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Share Forecast by Country (2027-2032) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Novel Oral AntiCoagulants (NOAC) Distributors List Table 209. Novel Oral AntiCoagulants (NOAC) Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Novel Oral AntiCoagulants (NOAC) Image Figure 2. Global Novel Oral AntiCoagulants (NOAC) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Novel Oral AntiCoagulants (NOAC) Market Size (2021-2032) & (US$ Million) Figure 4. Global Novel Oral AntiCoagulants (NOAC) Sales (2021-2032) & (W Units) Figure 5. Direct Thrombin Inhibitors Image Figure 6. Global Direct Thrombin Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 7. Direct Factor Xa Inhibitors Image Figure 8. Global Direct Factor Xa Inhibitors Sales YoY Growth (2021-2032) & (W Units) Figure 9. Global Novel Oral AntiCoagulants (NOAC) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Novel Oral AntiCoagulants (NOAC) Market Share by Type 2025 VS 2032 Figure 11. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Type in 2025 Figure 12. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Type in 2025 Figure 13. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Type in 2025 Figure 14. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Type in 2025 Figure 17. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Novel Oral AntiCoagulants (NOAC) Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hemodialysis Image Figure 24. Global Hemodialysis Sales YoY Growth (2021-2032) & (W Units) Figure 25. Deep Vein Thrombosis (DVT) Image Figure 26. Global Deep Vein Thrombosis (DVT) Sales YoY Growth (2021-2032) & (W Units) Figure 27. Acute Coronary Syndrome Image Figure 28. Global Acute Coronary Syndrome Sales YoY Growth (2021-2032) & (W Units) Figure 29. Pulmonary Embolism Image Figure 30. Global Pulmonary Embolism Sales YoY Growth (2021-2032) & (W Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 33. Global Novel Oral AntiCoagulants (NOAC) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Novel Oral AntiCoagulants (NOAC) Market Share by Application 2025 VS 2032 Figure 35. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Application in 2025 Figure 36. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Application in 2025 Figure 37. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Application in 2025 Figure 38. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Application in 2025 Figure 41. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share in Value by Application in 2025 Figure 45. North America Novel Oral AntiCoagulants (NOAC) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 46. North America Novel Oral AntiCoagulants (NOAC) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Novel Oral AntiCoagulants (NOAC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. Europe Novel Oral AntiCoagulants (NOAC) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Novel Oral AntiCoagulants (NOAC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Latin America Novel Oral AntiCoagulants (NOAC) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Novel Oral AntiCoagulants (NOAC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Novel Oral AntiCoagulants (NOAC) Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Novel Oral AntiCoagulants (NOAC) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Direct Thrombin Inhibitors
  • Direct Factor Xa Inhibitors
Applications
  • Hemodialysis
  • Deep Vein Thrombosis (DVT)
  • Acute Coronary Syndrome
  • Pulmonary Embolism
  • Others
Companies covered
  • Armatheon
  • Aspen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cellceutix
  • Cosmo Pharmaceuticals
  • CSL Behring
  • Daiichi Sankyo
  • Marathon Pharmaceuticals
  • Ockham Biotech
  • Perosphere
  • AstraZeneca
  • Bayer
  • GSK
  • Johnson & Johnson
  • Sanofi
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Novel Oral AntiCoagulants (NOAC) Market by Type
  6. 1.3.1 Direct Thrombin Inhibitors
  7. 1.3.2 Direct Factor Xa Inhibitors
  8. 1.4 Global Novel Oral AntiCoagulants (NOAC) Market Size by Type
  9. 1.4.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Novel Oral AntiCoagulants (NOAC) Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Novel Oral AntiCoagulants (NOAC) Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
  2. 2.2 Novel Oral AntiCoagulants (NOAC) Industry Drivers
  3. 2.3 Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges
  4. 2.4 Novel Oral AntiCoagulants (NOAC) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Novel Oral AntiCoagulants (NOAC) Revenue (2021-2026)
  2. 3.2 Global Top Players by Novel Oral AntiCoagulants (NOAC) Sales (2021-2026)
  3. 3.3 Global Top Players by Novel Oral AntiCoagulants (NOAC) Price (2021-2026)
  4. 3.4 Global Novel Oral AntiCoagulants (NOAC) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Novel Oral AntiCoagulants (NOAC) Major Company Production Sites & Headquarters
  6. 3.6 Global Novel Oral AntiCoagulants (NOAC) Company, Product Type & Application
  7. 3.7 Global Novel Oral AntiCoagulants (NOAC) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Novel Oral AntiCoagulants (NOAC) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Novel Oral AntiCoagulants (NOAC) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Novel Oral AntiCoagulants (NOAC) Tier 1, Tier 2, and Tier 3
4 Novel Oral AntiCoagulants (NOAC) Regional Status and Outlook
  1. 4.1 Global Novel Oral AntiCoagulants (NOAC) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Novel Oral AntiCoagulants (NOAC) Historic Market Size by Region
  3. 4.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Novel Oral AntiCoagulants (NOAC) Forecasted Market Size by Region
  7. 4.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Novel Oral AntiCoagulants (NOAC) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Novel Oral AntiCoagulants (NOAC) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Novel Oral AntiCoagulants (NOAC) by Application
  1. 5.1 Novel Oral AntiCoagulants (NOAC) Market by Application
  2. 5.1.1 Hemodialysis
  3. 5.1.2 Deep Vein Thrombosis (DVT)
  4. 5.1.3 Acute Coronary Syndrome
  5. 5.1.4 Pulmonary Embolism
  6. 5.1.5 Others
  7. 5.2 Global Novel Oral AntiCoagulants (NOAC) Market Size by Application
  8. 5.2.1 Global Novel Oral AntiCoagulants (NOAC) Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Novel Oral AntiCoagulants (NOAC) Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Novel Oral AntiCoagulants (NOAC) Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Armatheon
  2. 6.1.1 Armatheon Company Information
  3. 6.1.2 Armatheon Business Overview
  4. 6.1.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio
  6. 6.1.5 Armatheon Recent Developments
  7. 6.2 Aspen
  8. 6.2.1 Aspen Company Information
  9. 6.2.2 Aspen Business Overview
  10. 6.2.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio
  12. 6.2.5 Aspen Recent Developments
  13. 6.3 Boehringer Ingelheim
  14. 6.3.1 Boehringer Ingelheim Company Information
  15. 6.3.2 Boehringer Ingelheim Business Overview
  16. 6.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio
  18. 6.3.5 Boehringer Ingelheim Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Cellceutix
  26. 6.5.1 Cellceutix Company Information
  27. 6.5.2 Cellceutix Business Overview
  28. 6.5.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio
  30. 6.5.5 Cellceutix Recent Developments
  31. 6.6 Cosmo Pharmaceuticals
  32. 6.6.1 Cosmo Pharmaceuticals Company Information
  33. 6.6.2 Cosmo Pharmaceuticals Business Overview
  34. 6.6.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  36. 6.6.5 Cosmo Pharmaceuticals Recent Developments
  37. 6.7 CSL Behring
  38. 6.7.1 CSL Behring Company Information
  39. 6.7.2 CSL Behring Business Overview
  40. 6.7.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio
  42. 6.7.5 CSL Behring Recent Developments
  43. 6.8 Daiichi Sankyo
  44. 6.8.1 Daiichi Sankyo Company Information
  45. 6.8.2 Daiichi Sankyo Business Overview
  46. 6.8.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio
  48. 6.8.5 Daiichi Sankyo Recent Developments
  49. 6.9 Marathon Pharmaceuticals
  50. 6.9.1 Marathon Pharmaceuticals Company Information
  51. 6.9.2 Marathon Pharmaceuticals Business Overview
  52. 6.9.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  54. 6.9.5 Marathon Pharmaceuticals Recent Developments
  55. 6.10 Ockham Biotech
  56. 6.10.1 Ockham Biotech Company Information
  57. 6.10.2 Ockham Biotech Business Overview
  58. 6.10.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio
  60. 6.10.5 Ockham Biotech Recent Developments
  61. 6.11 Perosphere
  62. 6.11.1 Perosphere Company Information
  63. 6.11.2 Perosphere Business Overview
  64. 6.11.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio
  66. 6.11.5 Perosphere Recent Developments
  67. 6.12 AstraZeneca
  68. 6.12.1 AstraZeneca Company Information
  69. 6.12.2 AstraZeneca Business Overview
  70. 6.12.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio
  72. 6.12.5 AstraZeneca Recent Developments
  73. 6.13 Bayer
  74. 6.13.1 Bayer Company Information
  75. 6.13.2 Bayer Business Overview
  76. 6.13.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio
  78. 6.13.5 Bayer Recent Developments
  79. 6.14 GSK
  80. 6.14.1 GSK Company Information
  81. 6.14.2 GSK Business Overview
  82. 6.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio
  84. 6.14.5 GSK Recent Developments
  85. 6.15 Johnson & Johnson
  86. 6.15.1 Johnson & Johnson Company Information
  87. 6.15.2 Johnson & Johnson Business Overview
  88. 6.15.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio
  90. 6.15.5 Johnson & Johnson Recent Developments
  91. 6.16 Sanofi
  92. 6.16.1 Sanofi Company Information
  93. 6.16.2 Sanofi Business Overview
  94. 6.16.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio
  96. 6.16.5 Sanofi Recent Developments
  97. 6.17 Eisai
  98. 6.17.1 Eisai Company Information
  99. 6.17.2 Eisai Business Overview
  100. 6.17.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio
  102. 6.17.5 Eisai Recent Developments
7 North America by Country
  1. 7.1 North America Novel Oral AntiCoagulants (NOAC) Sales by Country
  2. 7.1.1 North America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026)
  4. 7.1.3 North America Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Novel Oral AntiCoagulants (NOAC) Market Size by Country
  6. 7.2.1 North America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026)
  8. 7.2.3 North America Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country
  2. 8.1.1 Europe Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026)
  4. 8.1.3 Europe Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country
  6. 8.2.1 Europe Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country
  2. 9.1.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size by Country
  6. 9.2.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Novel Oral AntiCoagulants (NOAC) Sales by Country
  2. 10.1.1 South America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026)
  4. 10.1.3 South America Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Novel Oral AntiCoagulants (NOAC) Market Size by Country
  6. 10.2.1 South America Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026)
  8. 10.2.3 South America Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country
  2. 11.1.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size by Country
  6. 11.2.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Novel Oral AntiCoagulants (NOAC) Value Chain Analysis
  2. 12.1.1 Novel Oral AntiCoagulants (NOAC) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Novel Oral AntiCoagulants (NOAC) Production Mode & Process
  7. 12.2 Novel Oral AntiCoagulants (NOAC) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
  10. 12.2.3 Novel Oral AntiCoagulants (NOAC) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst